Figure 1 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2

Figure 1 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2

<p>METAP2 inhibition measured in whole blood following increasing subcutaneous doses of SDX-7320. Blood samples obtained at the indicated times postdose were processed for measurement of uninhibited METAP2 using a capture ELISA as described in the “see Materials and Methods” section.</p>...

Cur síos iomlán

Sábháilte in:
Sonraí bibleagrafaíochta
Príomhchruthaitheoir: Monica M. Mita (21585118) (author)
Rannpháirtithe: Alain C. Mita (21585121) (author), Bradley J. Carver (18491067) (author), James M. Shanahan (18491064) (author), Benjamin A. Mayes (18491052) (author), Pierre J. Dufour (18491061) (author), David Browning (21585124) (author), Alfred Anderson-Villaluz (21585127) (author), John S. Petersen (18491055) (author), David J. Turnquist (18491058) (author), Peter Cornelius (18491049) (author)
Foilsithe / Cruthaithe: 2025
Ábhair:
Cancer
Cancer Detection and Diagnosis
Therapeutic Research and Development
Clinical Research and Trials
Biomarkers
Protein biomarkers
Pharmacology
Pharmacokinetics and pharmacodynamics
Phase I Clinical Trials
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla